varespladib has been researched along with MODS in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abraham, E; Bandi, V; Dmitrienko, A; Farid, N; Forgue, ST; Gervich, D; Jiang, F; Lowry, SF; Macias, W; Naum, C; Schein, RM; Skerjanec, S; Wunderink, R | 1 |
| Abraham, E; Dmitrienko, A; Fukiishi, Y; Laterre, PF; Steingrub, J; Zeiher, BG | 1 |
2 trial(s) available for varespladib and MODS
| Article | Year |
|---|---|
Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure.
Topics: Acetates; Aged; Cause of Death; Critical Illness; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; Female; Group II Phospholipases A2; Hospital Mortality; Humans; Indoles; Inflammation; Infusions, Intravenous; Keto Acids; Male; Middle Aged; Molecular Weight; Multiple Organ Failure; Phospholipases A; Phospholipases A2; Proportional Hazards Models; Prospective Studies; Safety; Survival Analysis; Systemic Inflammatory Response Syndrome; Time Factors; Treatment Outcome; United States | 2003 |
LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis.
Topics: Acetates; Double-Blind Method; Europe; Female; Group II Phospholipases A2; Humans; Indoles; Infusions, Intravenous; Keto Acids; Male; Middle Aged; Multiple Organ Failure; Phospholipases A; Phospholipases A2; Risk; Sepsis; United States | 2005 |